Literature DB >> 11368130

The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder.

M Steiner1, S J Romano, S Babcock, J Dillon, C Shuler, C Berger, D Carter, R Reid, D Stewart, S Steinberg, R Judge.   

Abstract

OBJECTIVE: To determine the effectiveness of fluoxetine in alleviating physical symptoms of premenstrual dysphoric disorder.
DESIGN: Randomised, double-blind, placebo controlled, parallel study.
SETTING: Canadian University based outpatient clinics. Participants Four hundred and five subjects, of whom 320 with prospectively determined premenstrual dysphoric disorder were randomised.
METHODS: Randomised women were assigned to fluoxetine 20 or 60 mg/day or placebo. Common physical symptoms associated with premenstrual dysphoric disorder including breast tenderness, bloating, and headache were evaluated by visual analog scales and the self-rated and observer premenstrual tension syndrome scales. OUTCOME MEASURES: Luteal phase change from mean baseline scores to mean treatment scores for all scales.
RESULTS: Fluoxetine treatment was statistically superior to placebo, with no significant differences between the two fluoxetine dosages in their effects on physical symptoms.
CONCLUSION: Daily fluoxetine treatment is superior to placebo in improving the most common physical symptoms associated with premenstrual dysphoric disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11368130     DOI: 10.1111/j.1471-0528.2001.00120.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  14 in total

Review 1.  Current update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

Review 2.  Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis.

Authors:  Maria Kleinstäuber; Michael Witthöft; Wolfgang Hiller
Journal:  J Clin Psychol Med Settings       Date:  2012-09

Review 3.  Gynecological management of premenstrual symptoms.

Authors:  Lee P Shulman
Journal:  Curr Pain Headache Rep       Date:  2010-10

Review 4.  Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?

Authors:  Uriel Halbreich; P M Shaughn O'Brien; Elias Eriksson; Torbjörn Bäckström; Kimberly A Yonkers; Ellen W Freeman
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  GPER1 stimulation alters posttranslational modification of RGSz1 and induces desensitization of 5-HT1A receptor signaling in the rat hypothalamus.

Authors:  Carrie E McAllister; Zhen Mi; Minae Mure; Qian Li; Nancy A Muma
Journal:  Neuroendocrinology       Date:  2014-11-07       Impact factor: 4.914

6.  The influence of early life sexual abuse on oxytocin concentrations and premenstrual symptomatology in women with a menstrually related mood disorder.

Authors:  Shannon K Crowley; Cort A Pedersen; Jane Leserman; Susan S Girdler
Journal:  Biol Psychol       Date:  2015-04-17       Impact factor: 3.251

Review 7.  Selective serotonin reuptake inhibitors for premenstrual syndrome.

Authors:  Jane Marjoribanks; Julie Brown; Patrick Michael Shaughn O'Brien; Katrina Wyatt
Journal:  Cochrane Database Syst Rev       Date:  2013-06-07

Review 8.  Premenstrual syndrome.

Authors:  Irene Kwan; Joseph Loze Onwude
Journal:  BMJ Clin Evid       Date:  2015-08-25

9.  Premenstrual Dysphoric Disorder: Recognition and Treatment.

Authors:  Ellen W. Freeman; Steven J. Sondheimer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-02

Review 10.  Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?

Authors:  Teri Pearlstein
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.